True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Company Growth (employees)
Type
Private
HQ
South San Francisco, US
Founded
2013
Size (employees)
19 (est)+6%
True North Therapeutics was founded in 2013 and is headquartered in South San Francisco, US

Key People at True North Therapeutics

Nancy Stagliano

Nancy Stagliano

CEO

True North Therapeutics Office Locations

True North Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
951 Gateway Blvd

True North Therapeutics Data and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$142 m

Latest funding size

$45 m

Time since last funding

7 months

Investors

True North Therapeutics's latest funding round in October 2016 was reported to be $45 m. In total, True North Therapeutics has raised $142 m

True North Therapeutics Company Life and Culture

You may also be interested in